Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JTT-861 in Heart Failure With Reduced Ejection Fraction
NCT06017609Phase 2Completed
- Sponsor
- Akros Pharma Inc.
- Start
- Dec 2023
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of JTT-861 in chronic heart failure (CHF), sponsored by Akros Pharma Inc.. Started Dec 2023; status: completed.
02
Drugs
JTT-861
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT06017609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06017609.